Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
Abstract The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with loca...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-01-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13045-016-0368-9 |
| _version_ | 1828339592521056256 |
|---|---|
| author | Yu Huang Bo Jia Shiyu Jiang Shengyu Zhou Jianliang Yang Peng Liu Lin Gui Xiaohui He Yan Qin Yan Sun Yuankai Shi |
| author_facet | Yu Huang Bo Jia Shiyu Jiang Shengyu Zhou Jianliang Yang Peng Liu Lin Gui Xiaohui He Yan Qin Yan Sun Yuankai Shi |
| author_sort | Yu Huang |
| collection | DOAJ |
| description | Abstract The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with localized SN-ENKTL. The age distribution for these two subtypes is very distinct and the B symptoms were more common in SN-ENKTL. However, both SN-DLBCL and SN-ENKTL patients could achieve high overall response rate (ORR) and favorable prognoses. The 3-year overall survival (OS) rates for patients with SN-DLBCL and SN-ENKTL were 79.7 and 83.6% (p = 0.707), and the 3-year progression-free survival (PFS) rates were 61.4 and 70.1% (p = 0.294), respectively. For SN-DLBCL patients, chemotherapy followed by involved-field radiotherapy (IFRT) resulted in higher OS (83.7 vs 62.5%) and PFS (63.9 vs 50.0%) compared with chemotherapy alone, but the difference was not significant. No significant difference was found in the OS or PFS between radiotherapy alone and radiotherapy combined with chemotherapy for all patients with SN-ENKTL. But in extensive stage I and stage II SN-ENKTL patients, radiotherapy combined with chemotherapy could significantly improve the PFS (73.8 vs 50.0%) compared with radiotherapy alone. These results indicate that remarkable clinical disparities exist between localized SN-DLBCL and SN-ENKTL. However, different treatment strategies for them can result in similarly favorable prognoses. |
| first_indexed | 2024-04-13T22:44:50Z |
| format | Article |
| id | doaj.art-af85ac2a4f0845d0bd1f84dc0902e13b |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-13T22:44:50Z |
| publishDate | 2017-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-af85ac2a4f0845d0bd1f84dc0902e13b2022-12-22T02:26:26ZengBMCJournal of Hematology & Oncology1756-87222017-01-011011410.1186/s13045-016-0368-9Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphomaYu Huang0Bo Jia1Shiyu Jiang2Shengyu Zhou3Jianliang Yang4Peng Liu5Lin Gui6Xiaohui He7Yan Qin8Yan Sun9Yuankai Shi10Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma (SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47 patients with localized SN-DLBCL and 211 patients with localized SN-ENKTL. The age distribution for these two subtypes is very distinct and the B symptoms were more common in SN-ENKTL. However, both SN-DLBCL and SN-ENKTL patients could achieve high overall response rate (ORR) and favorable prognoses. The 3-year overall survival (OS) rates for patients with SN-DLBCL and SN-ENKTL were 79.7 and 83.6% (p = 0.707), and the 3-year progression-free survival (PFS) rates were 61.4 and 70.1% (p = 0.294), respectively. For SN-DLBCL patients, chemotherapy followed by involved-field radiotherapy (IFRT) resulted in higher OS (83.7 vs 62.5%) and PFS (63.9 vs 50.0%) compared with chemotherapy alone, but the difference was not significant. No significant difference was found in the OS or PFS between radiotherapy alone and radiotherapy combined with chemotherapy for all patients with SN-ENKTL. But in extensive stage I and stage II SN-ENKTL patients, radiotherapy combined with chemotherapy could significantly improve the PFS (73.8 vs 50.0%) compared with radiotherapy alone. These results indicate that remarkable clinical disparities exist between localized SN-DLBCL and SN-ENKTL. However, different treatment strategies for them can result in similarly favorable prognoses.http://link.springer.com/article/10.1186/s13045-016-0368-9Diffuse large B cell lymphomaExtranodal NK/T cell lymphomaSinonasalLocalized |
| spellingShingle | Yu Huang Bo Jia Shiyu Jiang Shengyu Zhou Jianliang Yang Peng Liu Lin Gui Xiaohui He Yan Qin Yan Sun Yuankai Shi Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma Journal of Hematology & Oncology Diffuse large B cell lymphoma Extranodal NK/T cell lymphoma Sinonasal Localized |
| title | Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma |
| title_full | Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma |
| title_fullStr | Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma |
| title_full_unstemmed | Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma |
| title_short | Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma |
| title_sort | different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large b cell lymphoma and extranodal nk t cell lymphoma |
| topic | Diffuse large B cell lymphoma Extranodal NK/T cell lymphoma Sinonasal Localized |
| url | http://link.springer.com/article/10.1186/s13045-016-0368-9 |
| work_keys_str_mv | AT yuhuang differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT bojia differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT shiyujiang differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT shengyuzhou differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT jianliangyang differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT pengliu differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT lingui differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT xiaohuihe differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT yanqin differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT yansun differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma AT yuankaishi differentclinicalcharacteristicsandtreatmentstrategiesforpatientswithlocalizedsinonasaldiffuselargebcelllymphomaandextranodalnktcelllymphoma |